The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer
暂无分享,去创建一个
M. Dowsett | Z. Ghazoui | I. Smith | R. A’Hern | S. Pancholi | Susana Banerjee | S. Banerjee | L. Martin
[1] J. Fricker. San Antonio Breast Cancer Symposium. , 2009, The Lancet. Oncology.
[2] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[4] E. Perez,et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100 , 2006 .
[5] M. Dowsett,et al. Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer , 2006, Clinical Cancer Research.
[6] H. Kurzen,et al. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma , 2005, Melanoma research.
[7] C. Dabrosin,et al. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells , 2005, British Journal of Cancer.
[8] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Fernö,et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Mariani,et al. The Combination of the Selective Cyclooxygenase‐2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second‐Line Therapy for Non‐Small Cell Lung Cancer: A Phase II Study with Biological Correlates , 2005, Cancer journal.
[11] M. Dowsett,et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Funata,et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer , 2005, British Journal of Cancer.
[13] S. Postovsky,et al. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE IN PEDIATRIC MALIGNANCIES , 2005, Pediatric hematology and oncology.
[14] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[15] L. Rydén,et al. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response , 2004, Breast Cancer Research and Treatment.
[16] C. Dabrosin,et al. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. , 2003, Cancer research.
[17] P. Span,et al. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma , 2003, Cancer.
[18] Mitch Dowsett,et al. Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.
[19] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[20] J. Milanini,et al. Transcriptional Regulation of Vascular Endothelial Growth Factor by Estradiol and Tamoxifen in Breast Cancer Cells: A Complex Interplay between Estrogen Receptors α and β , 2002 .
[21] M. Dowsett,et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] Masakazu,et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐1 relationship in breast cancer , 2002, International journal of cancer.
[23] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[24] H. Matsubara,et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma , 2001, Cancer.
[25] T. H. van der Kwast,et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.
[26] M. Mueller,et al. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] R Bicknell,et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.
[28] G. Conway,et al. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. , 2000, Fertility and sterility.
[29] B. Bonanni,et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Karkkainen,et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.
[31] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] P. Boyle,et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. , 1998, British Journal of Cancer.
[33] P. Vermeulen,et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.
[34] S. Fox,et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] J. Feyzi,et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.
[36] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.